Connecting with the Jury: Mike Gay On Trial

In a recent Brainwaves event hosted by the Society of Automotive Analysts and Foley & Lardner LLP, titled “100 Days and Beyond: Presidential Policy Shifts Impacting Automotive,” business and legal executives gathered in Detroit to discuss the significant shifts in presidential policies and their profound impact on the automotive sector.

Foley & Lardner LLP recently co-hosted a webinar with the National Association of Corporate Directors to discuss how a new presidential administration and evolving state-driven regulations are effecting boardrooms.

On March 5, 2025, one U.S. District Court ruled unequivocally in the Food & Drug Administration’s (FDA) favor in the case, Outsourcing Facilities Ass’n, et. al. v. U.S. Food and Drug Admin., et. al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15  (N.D. Tex. Mar. 5, 2025), denying plaintiffs’ motion for (1) a preliminary injunction (PI) prohibiting the FDA from taking action against Outsourcing Facilities Association (OFA) members and FarmaKeio based on their compounding of the drug ingredient tirzepatide pending final judgment in the case and (2) a stay pending conclusion of the review proceedings in response to the FDA’s declaration that the shortage of the diabetes and weight-loss tirzepatide products has been resolved.